Skip to content

Alpha Cognition ACOG Product Net — Revenue

Other product segments

License
$29.98K-98.8%

Similar metrics at other companies

Geron logo
GERNProduct revenue, net — Total revenues
$51.77M+31.3%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
PTH
PTHSNet product revenues — Total Revenue
$10.67M
Aurinia Pharmaceuticals logo
AUPHNet product sales — Revenue
$73.56M+22.7%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%

Other financials

Income statement

See full
Revenue$3.5M+20.7%
Gross profit$3.3M+12.7%
Operating income-$8.1M-138%
Net income-$6.5M-276%
EPS (diluted)-$0.32-191%

Balance sheet

See full
Cash & equivalents$54.3M+100,638%
Total equity$57.5M+49.2%
Total assets$69.2M+42.5%

Cash flow

See full
Operating cash flow-$11.8M-477%
CapEx$1.3K-97.9%
Free cash flow-$11.8M-460%

Valuation

See full
Market cap$157.21M+6.6%
P/S14.5×

Profitability

See full
Gross margin89.3%
Operating margin-250.1%
Net margin-232.2%
FCF margin-280.5%

Returns & leverage

See full
Return on equity-52.4%-5.3pp
Current ratio12.6×-4.5×

Where this comes from

Reported directly by Alpha Cognition in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Alpha Cognition’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alpha Cognition's product net — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alpha Cognition's product net — revenue?
Alpha Cognition (ACOG) reported product net — revenue of $3.5M in Q1 2026.
How has Alpha Cognition's product net — revenue changed year-over-year?
Alpha Cognition's product net — revenue increased by 910.0% year-over-year, from $346.93K to $3.5M.
What does product net — revenue mean?
This metric represents the total net revenue generated from the sale of the company's commercialized pharmaceutical products after accounting for returns, discounts, and allowances. It serves as a primary indicator of market adoption and the commercial success of the company's therapeutic portfolio in treating neurodegenerative conditions. Tracking this figure allows investors to evaluate the company's transition from a development-stage entity to a commercial-stage biopharmaceutical business.